Telehealth services and mental health apps are storming the acute agitation and aggression treatment market during the ongoing coronavirus pandemic. Since increasing number of individuals are unable to afford treatment or medications, affordable telehealth services and mental health apps are helping to reduce anxiety among individuals.
Online pharmacies in the acute agitation and aggression treatment market are increasing their visibility digitally to help individuals compare the prices of medications. Manufacturers are maintaining optimum inventory levels to ensure a continuous supply of therapeutics. An increasing number of pharmaceutical companies are providing coupons and price reduction promo codes to help individuals purchase medications. Even insurance providers are refilling the prescription of patients well before the refill date in order to improve patient quality of life.
To know the scope of our report Get a Sample on Acute Agitation and Aggression Treatment Market
Like all medications, even antidepressants are associated with side effects such as headache, nausea, and insomnia in many cases. Hence, companies in the acute agitation and aggression treatment market are continuously investing in R&D to develop improved formulations of antidepressants. As such, antidepressants such as serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and atypical antidepressants are well-tolerated in individuals.
In order to reduce reliance on antidepressants, healthcare providers are increasing emphasis on behavioral approaches including lifestyle changes, brain stimulation therapies, and integrative medicines in order to improve patient outcomes. There is a growing awareness about different forms of psychotherapy that are helping patients suffering from depression. Cognitive behavioral therapy (CBT), diet changes, and family therapy are being publicized to improve patient quality of life.
Get a glimpse of the in-depth analysis through our Report Brochure
The acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% during the forecast period. Manufacturers are increasing the production of benzodiazepines for the rapid treatment of acute agitation in the emergency department (ED). Benzodiazepines are being known for sedating an undifferentiated patient without obvious delirium or psychiatric disease. However, benzodiazepines carry the risk of creating a paradoxical reaction in patients, especially the elderly and young population. As such, it has been found that benzodiazepines are well-tolerated and adverse reactions are rare.
Healthcare providers in the acute agitation and aggression treatment market are increasing awareness that benzodiazepines carry the risk for respiratory depression and hence must be avoided for patients who have ingested other depressant medications.
The acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031. Acute agitation is a frequent occurrence in both inpatient and outpatient psychiatric settings. This is acting as a key driver for market growth. Manufacturers in the acute agitation and aggression treatment market are increasing their production for Lorazepam, which is a type of benzodiazepine that is being extensively used for the management of acute agitation.
Lorazepam is being publicized as a clinically effective means of treating acutely agitated patients. This medication is being frequently used as the sedative and anxiolytic of choice in inpatient settings due to its rapid onset of action when administered intravenously.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Several brick and mortar pharmacies have started offering telemedicine services to help patients stock their medications during the ongoing COVID-19 pandemic. Apart from medications, healthcare providers in the acute agitation and aggression treatment market are providing non-pharmacologic de-escalation techniques including verbal de-escalation, combined with re-orientation and successive attempts at a therapeutic alliance. Sedation related adverse events, owing to medications should be overcome with increased research in well-tolerated therapeutic formulations. Manufacturers are producing Olanzapine for the treatment of agitation meant for intravenous administration. Midazolam, on the other hand, is being made available for intranasal and oral route of administration in acutely agitated patients, especially in EDs.
Attribute |
Detail |
Market Size Value in 2020 |
US$ 4.10 Bn |
Market Forecast Value in 2031 |
US$ 7.09 Bn |
Growth Rate (CAGR) |
5.1% |
Forecast Period |
2021–2031 |
Quantitative Units |
US$ Mn for Value |
Market Analysis |
The report scope includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key industry events, product analysis, technological advancement, etc. |
Competition Landscape |
Company Profiles section includes overview, business overview, strategy & recent developments, key financials, etc. |
Format |
Electronic (PDF) + Excel |
Regions Covered |
|
Countries Covered |
|
Market Segmentation |
|
Companies Profiled |
|
Customization Scope |
Available upon request |
Pricing |
Available upon request |
Acute Agitation and Aggression Treatment Market – Segmentation
Treatment Approach |
|
Indication |
|
Route of Administration |
|
End-user |
|
Region |
|
Acute agitation and aggression treatment market is projected to cross the value of US$ 7.09 Bn by 2031
Acute agitation and aggression treatment market is predicted to expand at a modest CAGR of 5.1% from 2021 to 2031
Acute agitation and aggression treatment market is driven by increase in incidence of dementia in geriatric population
North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period
Key players in the global acute agitation and aggression treatment market include Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Agitation and Aggression Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Patient journey Analysis
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.4. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.5. Pros and Cons of current Treatment for Acute Agitation and Aggression
5.6. Technological Advancements
6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Approach, 2017–2031
6.3.1. Behavioral Approaches
6.3.2. Environmental Interventions
6.3.3. Pharmacologic Approaches (Drugs)
6.3.3.1. Lorazepam
6.3.3.2. Chlorpromazine
6.3.3.3. Quetiapine
6.3.3.4. Droperidol
6.3.3.5. Olanzapine
6.3.3.6. Ziprasidone
6.3.3.7. Others
6.4. Market Attractiveness Analysis, by Treatment Approach
7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Schizophrenia
7.3.2. Dementia
7.3.3. Bipolar Disorder
7.3.4. Depression
7.3.5. Drug-induced Agitation and Aggression
7.3.6. Alcohol Withdrawal
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Intramuscular
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals & Ambulatory Surgical Centers
9.3.2. Psychiatric Care Facilities
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Approach, 2017–2031
11.2.1. Behavioral Approaches
11.2.2. Environmental Interventions
11.2.3. Pharmacologic Approaches (Drugs)
11.2.3.1. Lorazepam
11.2.3.2. Chlorpromazine
11.2.3.3. Quetiapine
11.2.3.4. Droperidol
11.2.3.5. Olanzapine
11.2.4. Ziprasidone
11.2.4.1. Others
11.3. Market Value Forecast, by Indication, 2017–2031
11.3.1. Schizophrenia
11.3.2. Dementia
11.3.3. Bipolar Disorder
11.3.4. Depression
11.3.5. Drug-induced Agitation and Aggression
11.3.6. Alcohol Withdrawal
11.3.7. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Intramuscular
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals & Ambulatory Surgical Centers
11.5.2. Psychiatric Care Facilities
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Approach
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By End-user
11.7.5. By Country
12. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Approach, 2017–2031
12.2.1. Behavioral Approaches
12.2.2. Environmental Interventions
12.2.3. Pharmacologic Approaches (Drugs)
12.2.3.1. Lorazepam
12.2.3.2. Chlorpromazine
12.2.3.3. Quetiapine
12.2.3.4. Droperidol
12.2.3.5. Olanzapine
12.2.3.6. Ziprasidone
12.2.3.7. Others
12.3. Market Value Forecast, by Indication , 2017–2031
12.3.1. Schizophrenia
12.3.2. Dementia
12.3.3. Bipolar Disorder
12.3.4. Depression
12.3.5. Drug-induced Agitation and Aggression
12.3.6. Alcohol Withdrawal
12.3.7. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Intramuscular
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals & Ambulatory Surgical Centers
12.5.2. Psychiatric Care Facilities
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Approach
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Approach, 2017–2031
13.2.1. Behavioral Approaches
13.2.2. Environmental Interventions
13.2.3. Pharmacologic Approaches (Drugs)
13.2.3.1. Lorazepam
13.2.3.2. Chlorpromazine
13.2.3.3. Quetiapine
13.2.3.4. Droperidol
13.2.3.5. Olanzapine
13.2.3.6. Ziprasidone
13.2.3.7. Others
13.3. Market Value Forecast, by Indication, 2017–2031
13.3.1. Schizophrenia
13.3.2. Dementia
13.3.3. Bipolar Disorder
13.3.4. Depression
13.3.5. Drug-induced Agitation and Aggression
13.3.6. Alcohol Withdrawal
13.3.7. Others
13.4. Market Value Forecast, by Route of Administration , 2017–2031
13.4.1. Oral
13.4.2. Intramuscular
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals & Ambulatory Surgical Centers
13.5.2. Psychiatric Care Facilities
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Approach
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Approach, 2017–2031
14.2.1. Behavioral Approaches
14.2.2. Environmental Interventions
14.2.3. Pharmacologic Approaches (Drugs)
14.2.3.1. Lorazepam
14.2.3.2. Chlorpromazine
14.2.3.3. Quetiapine
14.2.3.4. Droperidol
14.2.3.5. Olanzapine
14.2.4. Ziprasidone
14.2.4.1. Others
14.3. Market Value Forecast, by Indication , 2017–2031
14.3.1. Schizophrenia
14.3.2. Dementia
14.3.3. Bipolar Disorder
14.3.4. Depression
14.3.5. Drug-induced Agitation and Aggression
14.3.6. Alcohol Withdrawal
14.3.7. Others
14.4. Market Value Forecast, by Route of Administration , 2017–2031
14.4.1. Oral
14.4.2. Intramuscular
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals & Ambulatory Surgical Centers
14.5.2. Psychiatric Care Facilities
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Approach
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Approach, 2017–2031
15.2.1. Behavioral Approaches
15.2.2. Environmental Interventions
15.2.3. Pharmacologic Approaches (Drugs)
15.2.3.1. Lorazepam
15.2.3.2. Chlorpromazine
15.2.3.3. Quetiapine
15.2.3.4. Droperidol
15.2.3.5. Olanzapine
15.2.4. Ziprasidone
15.2.4.1. Others
15.3. Market Value Forecast, by Indication, 2017–2031
15.3.1. Schizophrenia
15.3.2. Dementia
15.3.3. Bipolar Disorder
15.3.4. Depression
15.3.5. Drug-induced Agitation and Aggression
15.3.6. Alcohol Withdrawal
15.3.7. Others
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Intramuscular
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals and Ambulatory Surgical Centers
15.5.2. Psychiatric Care Facilities
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Treatment Approach
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Company Profiles
16.2.1. Eli Lilly and Company
16.2.1.1. Company Overview
16.2.1.2. Company Financials
16.2.1.3. Growth Strategies
16.2.1.4. SWOT Analysis
16.2.2. Pfizer, Inc.
16.2.2.1. Company Overview
16.2.2.2. Company Financials
16.2.2.3. Growth Strategies
16.2.2.4. SWOT Analysis
16.2.3. Otsuka Holdings
16.2.3.1. Company Overview
16.2.3.2. Company Financials
16.2.3.3. Growth Strategies
16.2.3.4. SWOT Analysis
16.2.4. GlaxoSmithKline
16.2.4.1. Company Overview
16.2.4.2. Company Financials
16.2.4.3. Growth Strategies
16.2.4.4. SWOT Analysis
16.2.5. H. Lundbeck A/S
16.2.5.1. Company Overview
16.2.5.2. Company Financials
16.2.5.3. Growth Strategies
16.2.5.4. SWOT Analysis
16.2.6. Johnson & Johnson
16.2.6.1. Company Overview
16.2.6.2. Company Financials
16.2.6.3. Growth Strategies
16.2.6.4. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd.
16.2.7.1. Company Overview
16.2.7.2. Company Financials
16.2.7.3. Growth Strategies
16.2.7.4. SWOT Analysis
16.2.8. Amneal Pharmaceuticals LLC
16.2.8.1. Company Overview
16.2.8.2. Company Financials
16.2.8.3. Growth Strategies
16.2.8.4. SWOT Analysis
16.2.9. Sun Pharmaceutical Industries Ltd.
16.2.9.1. Company Overview
16.2.9.2. Company Financials
16.2.9.3. Growth Strategies
16.2.9.4. SWOT Analysis
16.2.10. F. Hoffmann-La Roche Ltd.
16.2.10.1. Company Overview
16.2.10.2. Company Financials
16.2.10.3. Growth Strategies
16.2.10.4. SWOT Analysis
16.2.11. Bausch Health Companies, Inc.
16.2.11.1. Company Overview
16.2.11.2. Company Financials
16.2.11.3. Growth Strategies
16.2.11.4. SWOT Analysis
16.2.12. Apotex, Inc.
16.2.12.1. Company Overview
16.2.12.2. Company Financials
16.2.12.3. Growth Strategies
16.2.12.4. SWOT Analysis
16.2.13. Aurobindo Pharma
16.2.13.1. Company Overview
16.2.13.2. Company Financials
16.2.13.3. Growth Strategies
16.2.13.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis - Acute Agitation and Aggression Treatment
Table 02: Oral Medications For Clinically Significant Acute Agitation
Table 03: Parenteral Medications For Clinically Significant Acute Agitation
Table 04: Pros and Cons of Non-pharmacologic Interventions for Acute Agitation
Table 05: Pros and Cons of Pharmacologic Interventions (Different routes of administration) For Acute Agitation
Table 06: Pros and Cons of Pharmacologic Interventions (Oral) For Acute Agitation
Table 07: Pros and Cons of Pharmacologic Interventions For Acute Agitation
Table 08: Pharmacology of drugs commonly used for Acute Agitation and Aggression
Table 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 14: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 15: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 16: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 17: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 18: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031
Table 19: North America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 22: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 23: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 24: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031
Table 25: Europe Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 28: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 29: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031
Table 31: Asia Pacific Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 33: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 34: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 35: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 36: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031
Table 37: Latin America Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 38: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 39: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Treatment Approach, 2017–2031
Table 40: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, by Pharmacologic Approaches (Drugs), 2017–2031
Table 41: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 42: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by Indication, 2017–2031
Table 43: Middle East & Africa Acute Agitation and Aggression Treatment Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Agitation and Aggression Treatment Market Value Share, by Treatment Approach, 2020
Figure 03: Global Acute Agitation and Aggression Treatment Market Value Share, by Route of Administration, 2020
Figure 04: Global Acute Agitation and Aggression Treatment Market Value Share, by End-user, 2020
Figure 05: Global Acute Agitation and Aggression Treatment Market Value Share, by Indication , 2020
Figure 06: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 07: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 08: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Behavioral Approaches, 2017–2031
Figure 09: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Environmental Interventions, 2017–2031
Figure 10: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Pharmacologic Approaches (Drugs), 2017–2031
Figure 11: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Lorazepam, 2017–2031
Figure 12: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Chlorpromazine, 2017–2031
Figure 13: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Quetiapine, 2017–2031
Figure 14: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Droperidol, 2017–2031
Figure 15: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Olanzapine, 2017–2031
Figure 16: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Ziprasidone, 2017–2031
Figure 17: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031
Figure 18: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 19: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 20: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Oral, 2017–2031
Figure 21: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Intramuscular, 2017–2031
Figure 22: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031
Figure 23: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 24: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 25: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Schizophrenia, 2017–2031
Figure 26: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Dementia, 2017–2031
Figure 27: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Bipolar Disorder, 2017–2031
Figure 28: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Depression , 2017–2031
Figure 29: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Drug-induced agitation and aggression, 2017–2031
Figure 30: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Alcohol withdrawal, 2017–2031
Figure 31: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031
Figure 32: Global Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 33: Global Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 34: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Hospitals & Ambulatory Surgical Centers, 2017–2031
Figure 35: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Psychiatric Care Facilities, 2017–2031
Figure 36: North America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Global Acute Agitation and Aggression Treatment Market Value (US$ Mn), by Others, 2017–2031
Figure 38: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country, 2020 and 2031
Figure 39: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country, 2021–2031
Figure 40: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 41: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 42: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 43: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 44: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 45: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 46: North America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 47: North America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 48: Europe Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 49: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 50: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 51: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 52: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 53: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 54: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 55: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 56: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 57: Europe Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 58: Europe Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 59: Asia Pacific Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 60: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 61: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 62: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 63: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 64: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 65: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 66: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 67: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 68: Asia Pacific Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 69: Asia Pacific Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 70: Latin America Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 71: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 72: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 73: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 74: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 75: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 76: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 77: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 78: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 79: Latin America Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 80: Latin America Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031
Figure 81: Middle East & Africa Acute Agitation and Aggression Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 82: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 83: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 84: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Treatment Approach, 2020 and 2031
Figure 85: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Treatment Approach, 2021–2031
Figure 86: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 87: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 88: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by Indication, 2020 and 2031
Figure 89: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by Indication, 2021–2031
Figure 90: Middle East & Africa Acute Agitation and Aggression Treatment Market Value Share Analysis, by End-user, 2020 and 2031
Figure 91: Middle East & Africa Acute Agitation and Aggression Treatment Market Attractiveness Analysis, by End-user, 2021–2031